For the first time, researchers at Michigan Medicine have demonstrated that a cellular process known to be involved in cancer and other diseases also plays an important role in the growth of at least one type of normal mammalian cell.
Macropinocytosis is an ancient process by which cells take in large volumes of material from outside of themselves. The process is hijacked by certain cancer cells to gather proteins to break down into cellular fuel. The process is also exploited by viruses and bacteria to enter cells.
New findings from the lab of Philip D. King, Ph.D., professor of Microbiology & Immunology at the U-M Medical School and a member of the U-M Rogel Cancer Center, showed that both primary mouse and human T cells -; which play a central role in the immune response -; engage in macropinocytosis to support normal cell growth.
Our research suggests that this may be a more general phenomenon, applicable to the growth of other primary cell types." John Charpentier, study lead author, graduate student in King's lab
King adds, "Blocking macropinocytosis in cancer might not represent an effective means of treating cancer since it is predicted that the generation of an anti-tumor T cell immune response would also be inhibited using this approach." Source:
Michigan Medicine - University of Michigan Journal reference:
Charpentier, J. C., et al. (2020) Macropinocytosis drives T cell growth by sustaining the activation of mTORC1. Nature Communications . doi.org/10.1038/s41467-019-13997-3 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology